Firm brings in $10M for cancer therapies

TAMPA — Intezyne Technologies, a clinical-stage biopharmaceutical company developing anti-cancer therapies, closed an oversubscribed $10 million Series A Preferred financing round led by existing investor Gaston Capital Healthcare Fund.

According to a press release, Intezyne has two clinical-stage programs — known as IT-139 and IT-141 — that are investigating treatment solutions for gastric, pancreatic, lung, breast, colorectal and thyroid cancer, as well as melanoma.

As part of the financing, Gaston Capital President and COO David Robb and Chief Investment Officer Glenn Walthall joined Intezyne's board of directors.